SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specialising in cannabinoid-based medicines, together with Universidade Lusófona, has published their 4th peer-reviewed study titled “Genotype and chemotype insights of high-THC medicinal Cannabis sativa L.: the role of SSR markers in the identification of cultivars” in the Journal of Cannabis Research.
The paper presents a scientifically validated framework that supports genetic and chemical consistency in high-THC medicinal cannabis oils—reinforcing SOMAÍ’s commitment to evidence-based pharmaceutical manufacturing and regulatory excellence across global medical markets.
Key Findings From the Study
The research validates a two-pillar identity approach that supports precision and reproducibility in cannabis oil production:
- Genetic stability verified through Simple Sequence Repeat (SSR) markers in the cultivars studied, supporting the identification of true-to-type clones across batches.
- Chemical consistency showing reproducible levels of major cannabinoids throughout production cycles, with only minor compounds and impurities varying according to cultivar.
- Enhanced traceability, enabling clearer differentiation of plant origin, batch lineage, and cultivation cycles.
- A proposed unified genotype + chemotype identity fingerprint, suitable for pharmaceutical documentation and regulatory submissions.
In addition, the study demonstrates that SOMAÍ’s extraction and purification process can:
- Increase total cannabinoids to approximately 97%,
- Efficiently remove waxes and chlorophyll, and
- Preserve the characteristic cannabinoid profile from flower to final oil—an essential requirement for pharmaceutical consistency.
The study was conducted in close collaboration with the research team at Universidade Lusófona, whose expertise in molecular biology, chemotype analysis, and applied pharmaceutical science played a central role in developing and validating the methodology. By combining academic rigour with real-world EU-GMP manufacturing conditions, the collaboration ensured that the findings are not only scientifically robust but also directly applicable to regulated medical cannabis production.
Future-Ready: Why Pure Is Building the Cannabis Company Traditional Industry Will Want to Buy Into
What This Means for Pharmacies, Clinics & Patients
This peer-reviewed methodology offers scientific support for the reliability and pharmaceutical quality of SOMAÍ’s full-spectrum cannabis oils, enabling:
- More predictable dosing, an essential factor for patient safety and therapeutic consistency.
- Regulatory-ready documentation, aligned with evolving requirements in Europe, APAC, and LATAM.
- Reduced batch-to-batch variability, addressing one of the most significant concerns of prescribers and pharmacists.
- Greater product confidence, backed by measurable genetic and chemical verification rather than strain names or unverifiable clone claims.
- A more dependable supply chain, strengthening trust between manufacturers, clinics, and distribution partners in fast-growing medical cannabis markets.
This scientific validation bolsters SOMAÍ’s expanding portfolio of EU-GMP cannabis medicines and reinforces its position as a trusted pharmaceutical partner worldwide.
“At SOMAÍ, we are making more than an extensive product array; we continue to invest in scientific studies to differentiate our products for doctors and patients around the globe. With a belief that pharmaceutical cannabis demands the same rigor as any other medicinal product, this study demonstrates how genetics, chemistry, and GMP processes work together to guarantee consistency for patients and confidence for prescribers,” said Michael Sassano, Founder and Interim CEO of SOMAÍ. “As more markets adopt higher regulatory expectations, SOMAÍ will continue to be first in researching the future of cannabis-based extract medicines.”
“This research provides the scientific framework needed to guarantee batch-to-batch consistency in cannabis medicines. By integrating genotype and chemotype verification, we are able to confirm the reliability and reproducibility expected in any pharmaceutical product,” said Professor Maria do Céu Costa of Universidade Lusófona. “Working with SOMAÍ allowed us to translate this methodology directly into real-world EU-GMP manufacturing, ensuring patients benefit from truly standardised formulations.”
